Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Classificação em ações #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Preço da ação
$150.78
Última sincronização: 2026-09-18
Valor de mercado
$187.20B
Variação (1 dia)
-0.08%
Variação (1 ano)
32.15%
País
US
Negociar Gilead Sciences, Inc. (GILD)

Categoria

Receita da Gilead Sciences, Inc. (GILD)
Receita em Jun 2026 TTM: $30.46B
De acordo com os últimos relatórios financeiros da Gilead Sciences, Inc., a receita atual da empresa (TTM) é $30.46B. Em 2024, a empresa obteve uma receita de $28.75B um aumento em relação a a receita do ano 2023, que foi de $27.12B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Gilead Sciences, Inc. de 2000 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) $30.46B 3.44%
2025 $29.44B 2.40%
2024 $28.75B 6.04%
2023 $27.12B -0.60%
2022 $27.28B -0.09%
2021 $27.31B 10.60%
2020 $24.69B 9.98%
2019 $22.45B 1.46%
2018 $22.13B -15.24%
2017 $26.11B -14.09%
2016 $30.39B -6.89%
2015 $32.64B 31.13%
2014 $24.89B 122.19%
2013 $11.20B 15.46%
2012 $9.70B 15.70%
2011 $8.39B 5.48%
2010 $7.95B 13.38%
2009 $7.01B 31.40%
2008 $5.34B 26.14%
2007 $4.23B 39.78%
2006 $3.03B 49.19%
2005 $2.03B 53.13%
2004 $1.32B 52.63%
2003 $867.86M 85.92%
2002 $466.79M 99.68%
2001 $233.77M 19.54%
2000 $195.56M 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
$79.67B 161.58%
US
$97.93B 221.54%
US
$64.39B 111.41%
US
$77.52B 154.53%
CH
$66.40B 118.02%
US